search
Back to results

Exogenous Ketosis During Bed Rest in Older Adults (KBR)

Primary Purpose

Muscle Protein Synthesis, Muscle Atrophy, Insulin Sensitivity

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate
carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)
Sponsored by
McGill University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Muscle Protein Synthesis focused on measuring Bed rest, Muscle protein synthesis, Older adults, Muscle mitochondrial function, Insulin sensitivity, Ketone bodies

Eligibility Criteria

65 Years - 85 Years (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy, male, and female, older adults. Healthy will be defined as screen by the 2020 PAR-Q+, medical screening questionnaire, GAQ, and COVID-19 symptom questionnaire patient screening. 'Older' will be defined as being 65-85 years of age. Participants are required to not engage in structured resistance training for at least 6 months prior to participation in the study. Participants are willing to abide by the compliance rules of this study. Exclusion Criteria: Pre-menopausal females: Women must be postmenopausal having not menstruated for at least 1 year prior to study participation. Hormonal fluctuations associated with the menstrual cycle have been reported to alter protein metabolism and may influence indices of muscle protein synthesis and breakdown (69-71). BMI <18.5 or > 30 kg ∙ m-2. Self-reported regular tobacco use and vaping products. Self-reported illicit drug use (e.g., growth hormone, testosterone, etc.) Individuals who have participated in studies within the past year involving a stable isotope of 2H. A history of thrombosis, diagnosed with type 2 diabetes mellitus by physician or HbA1c values of > 7.0%, dementia, coronary artery disease, musculoskeletal/orthopedic disorders, and severe allergies. The use of medications known to modulate skeletal muscle metabolism (e.g., corticosteroids, hormone replacement therapy, non-steroidal anti-inflammatory drugs, metformin). The use of over-the-counter supplements (protein supplements, creatine, fish oil). Inability to adhere to any of the compliance rules judged by the principal investigator or medical doctor.

Sites / Locations

  • Research Institute - McGill University Health CentreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Exogenous ketone monoester (KET)

Energy matched control (CON)

Arm Description

KET will be provided at a dose of 360 mg kg-1 body mass per serving at 2 servings per day between each main meal (ΔG®; TΔS Ltd, UK, Oxford, UK).

CON will be provided at a dose energy matched to the KET supplement and consist of both carbohydrate (i.e., fructose) and fat (i.e., corn and canola oil 50:50 ratio). 1/3 of the supplemental energy will come from carbohydrate while 2/3 will come from fat. We have excluded protein from the CON supplement since it is well established to influence our primary outcome measure (MPS rates). A non-caloric sweetener will also be added to the CON supplement.

Outcomes

Primary Outcome Measures

Changes in integrated fractional synthesis rate (%/d) in response to bed rest with and without ketone monoester (KET) supplementation.
Integrative myofibrillar fractional synthesis rate will be calculated during baseline (day 0-5) and bed rest (day 5-10) phases.

Secondary Outcome Measures

Changes in whole body insulin sensitivity in response to bed rest with and without ketone monoester (KET) supplementation.
Measurements taken in the fasted state before and after bed rest. Will measure blood glucose and insulin concentration during a hyperinsulinemic-euglycemic clamp.
Changes in whole-body lean mass (kg) in response to bed rest with and without ketone monoester (KET) supplementation
Measurements taken in the fasted state using dual-energy x-ray absorptiometry (DXA) following urinary void before and after bed rest.
Changes in leg lean mass (kg) in response to bed rest with and without ketone monoester (KET) supplementation
Measurements taken in the fasted state using dual-energy x-ray absorptiometry (DXA) following urinary void before and after bed rest.
Changes in quadriceps muscle volume in response to bed rest with and without ketone monoester (KET) supplementation.
Measurements taken before and after bed rest via magnetic resonance imaging (MRI).
Changes in maximal voluntary isometric contraction (N/m) of the knee extensors in response to bed rest with and without ketone monoester (KET) supplementation.
Measurements taken before and after bed rest using a Biodex dynamometer.
Changes in handgrip strength (kg) in response to bed rest with and without ketone monoester (KET) supplementation.
Measurements taken before and after bed rest using a Jamar hand dynamometer.
Changes in physical performance (numerical score) as determined by short physical performance battery (SPPB) in response to bed rest with and without ketone monoester (KET) supplementation.
Measurements taken before and after bed rest
Changes in physical performance (numerical score) as determined by 5-item physical performance test in response to bed rest with and without ketone monoester (KET) supplementation.
Measurements taken before and after bed rest
Changes in cognitive status in response to bed rest with and without ketone monoester (KET) supplementation.
NIH Toolbox Cognition Battery (computerized). Measurements taken before and after bed rest
Changes in markers of inflammation in systemic circulation in response to bed rest with and without ketone monoester (KET) supplementation.
Markers of inflammation including: IL-1 beta, NF-K beta 1, IL-6, TNF-alpha, IFNY, MIP-1 beta will be evaluated. Measurements taken before, during, and after bed rest.
Changes in muscle mRNA expression of inflammatory regulators will be assessed in response to bed rest with and without ketone monoester (KET) supplementation.
Muscle mRNA expression of NFKB1, TLR-4,IL-6, TNF-alpha, and IL-1Beta will be evaluated. Measurements taken before and after bed rest
Changes in skeletal muscle phenotype in response to bed rest with and without ketone monoester (KET) supplementation.
Muscle cross-sections immunolabeled for type I, IIa, and IIx myosin heavy chains. Measurements taken before and after bed rest.
Changes in skeletal muscle fiber size in response to bed rest with and without ketone monoester (KET) supplementation.
Muscle cross-sections analyzed for cross-sectional area.
Changes in mitochondrial content in response to bed rest with and without ketone monoester (KET) supplementation.
Via the assessment in succinate dehydrogenase activity.
Changes in mitochondrial respiration in response to bed rest with and without ketone monoester (KET) supplementation.
Assessed using standard substrate and inhibitor addition protocols in O2k high resolution Respirometer. Measurements taken before and after bed rest.
Changes in mitochondrial calcium retention capacity (marker of mitochondrial propensity to trigger apoptosis) in response to bed rest with and without ketone monoester (KET) supplementation.
Determined spectrofluorometrically using the Calcium Green probe. Measurements taken before and after bed rest.
Changes in mitochondrial reactive oxygen species (ROS) production in response to bed rest with and without ketone monoester (KET) supplementation.
Assessed using standard substrate and inhibitor addition protocols in O2k high resolution Respirometer. Measurements taken before and after bed rest.
Changes in mitochondrial time to the permeability transition pore opening (marker of mitochondrial propensity to trigger apoptosis) in response to bed rest with and without ketone monoester (KET) supplementation.
Determined spectrofluorometrically using the Calcium Green probe. Measurements taken before and after bed rest.
Changes in the phosphorylation status of anabolic signaling molecules modulating muscle protein synthesis (MPS) in response to bed rest with and without ketone monoester (KET) supplementation.
Western blotting - membranes will be probed with phospho-specific antibodies against IRS-1S527/Thr446, AktSer473, mTORSer2448, 4E-BP1Thr37/46, rpS6Ser240/244, p70S6KThr389. Measurements taken before and after bed rest.
Changes in the phosphorylation status of catabolic signaling molecules modulating muscle protein breakdown (MPB) in response to bed rest with and without ketone monoester (KET) supplementation.
Western blotting - membranes will be probed with phospho-specific antibodies against FoxO3aThr32, MuRF1, and MAFbx. Measurements taken before and after bed rest.
Blood beta-hydroxybutyrate concentrations (mmol/L) in response to bed rest with and without ketone monoester (KET) supplementation.
Measurements taken at the start and end of bed rest.
Changes in subjective pain via visual analog scale in response to bed rest with and without ketone monoester (KET) supplementation.
Throughout the 5 day bed rest period.
Changes in muscle area in response to bed rest with and without ketone monoester (KET) supplementation.
Peripheral quantitative computed tomography (pQCT). Measurements taken before and after bed rest.
Changes in muscle density in response to bed rest with and without ketone monoester (KET) supplementation.
Peripheral quantitative computed tomography (pQCT). Measurements taken before and after bed rest.
2H enrichments in body water before and during bed rest with and without ketone monoester (KET) supplementation.
Throughout the baseline and bed rest period.
2H-alanine enrichment in venous blood before and during bed rest with and without ketone monoester (KET) supplementation.
Throughout the baseline and bed rest period.
Changes in resting metabolic rate (RMR) in response to bed rest with and without ketone monoester (KET) supplementation.
Measurements taken before and after bed rest.
Physical activity level via accelerometer before bed rest.
Throughout the baseline period
Changes in sleep disturbance (numerical score) during bed rest with and without ketone monoester (KET) supplementation.
Via Patient-Reported Outcomes Measurement Information System (PROMIS) Short form 8a. Measured throughout the 5 day bed rest period.
Changes in sleep quality (numerical score) during bed rest with and without ketone monoester (KET) supplementation.
Via Pittsburgh Sleep Quality Index (PSQI). Measured throughout the 5 day bed rest period.
Average habitual dietary intake assessed using Keenoa for 3 days (a food tracker application).
Dietary intake will be assessed for total energy (kcals) and macronutrient (protein, carbohydrate, and fat consumption; g) intake.
Changes in Thigh Absolute Synthetic Rate (ASR) in response to bed rest with and without ketone monoester (KET) supplementation.
Changes in Thigh Absolute Synthetic Rate (ASR) will be calculated during baseline (day 0-5) and bed rest (day 5-10) phases.
Changes in Thigh Absolute Protein Breakdown Rate (ABR) in response to bed rest with and without ketone monoester (KET) supplementation.
Changes in Thigh Absolute Protein Breakdown Rate (ABR) will be calculated during baseline (day 0-5) and bed rest (day 5-10) phases.

Full Information

First Posted
December 12, 2022
Last Updated
February 26, 2023
Sponsor
McGill University
Collaborators
Canadian Institutes of Health Research (CIHR)
search

1. Study Identification

Unique Protocol Identification Number
NCT05679596
Brief Title
Exogenous Ketosis During Bed Rest in Older Adults
Acronym
KBR
Official Title
Ketone Bodies as Therapeutic Agents to Reduce the Harmful Effects of Bed Rest on Muscle Mass and Metabolic Health in Older Adults
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 27, 2023 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
March 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University
Collaborators
Canadian Institutes of Health Research (CIHR)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this randomized, double-blind, parallel group interventional study is to evaluate the effect of ketone bodies on healthy older adults (65-85 y) during 5 days of bed rest. The main questions it aims to answer are: Does supplementation of ketone bodies prevent the typical decline in muscle protein synthesis, muscle size, muscle function, insulin sensitivity, and muscle mitochondrial function that occurs in response to bed rest? Researchers will compare ketone supplements (KET) to an energy matched control beverage (carbohydrates and fats) to see if the ketones can rescue the decline in muscle protein synthesis rates, muscle loss, muscle function, insulin sensitivity, and mitochondrial function due to 5 days of bed rest. This may positively impact the heath of older adults subjected to bed rest.
Detailed Description
Bed rest is a common feature of many clinical environments such as hospitals and long-term care facilities. However, physical inactivity due to bed rest decreases muscle size, muscle strength, and physical performance (i.e. rising from a chair) that can lead to a reduced quality of life and a higher risk of disease and death. Eating protein-rich foods and exercising normally helps to maintain muscle size by building proteins found in muscle. However, during bed rest there is a reduction in the rate at which proteins found in muscle are made and this leads to smaller muscles. Bed rest leads to problems with blood glucose regulation and insulin resistance which can increase the risk for diabetes. Both the loss of muscle size and insulin resistance are linked to problems with parts of our cells called mitochondria. Mitochondria do a lot of important things including keeping our cells full of energy. Bed rest occurs more frequently in older adults and also negatively impacts their health more than in younger adults. Sadly, there are limited options to prevent the problems associated with bed rest. Ketone bodies are molecules that come from fat that are normally produced in the body in response to reduced carbohydrate intake (i.e. a ketogenic diet). Recently ketone supplements have become available, which increase the amount of ketone bodies in the body without the need to limit carbohydrate intake from food. Elevated ketone bodies may help protect muscle size and health during bed rest by enhancing the process of building muscle proteins, improving blood glucose regulation, and helping mitochondria work optimally.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscle Protein Synthesis, Muscle Atrophy, Insulin Sensitivity, Mitochondrial Function, Physical Inactivity, Cognitive Function, Muscle Strength, Functional Capacity
Keywords
Bed rest, Muscle protein synthesis, Older adults, Muscle mitochondrial function, Insulin sensitivity, Ketone bodies

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, double-blind, parallel group study design.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Participants, Investigators and Outcome Accessors will be blinded to the intervention and control drinks. The drinks will be flavor and energy matched and provided in an opaque bottle. An individual not involved with the study data collection, analysis and interpretation will be designated as a study blinder and randomizer.
Allocation
Randomized
Enrollment
36 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Exogenous ketone monoester (KET)
Arm Type
Experimental
Arm Description
KET will be provided at a dose of 360 mg kg-1 body mass per serving at 2 servings per day between each main meal (ΔG®; TΔS Ltd, UK, Oxford, UK).
Arm Title
Energy matched control (CON)
Arm Type
Active Comparator
Arm Description
CON will be provided at a dose energy matched to the KET supplement and consist of both carbohydrate (i.e., fructose) and fat (i.e., corn and canola oil 50:50 ratio). 1/3 of the supplemental energy will come from carbohydrate while 2/3 will come from fat. We have excluded protein from the CON supplement since it is well established to influence our primary outcome measure (MPS rates). A non-caloric sweetener will also be added to the CON supplement.
Intervention Type
Dietary Supplement
Intervention Name(s)
ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate
Other Intervention Name(s)
delta G Oxford Ketone Ester
Intervention Description
Provided twice a day between meals.
Intervention Type
Dietary Supplement
Intervention Name(s)
carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)
Intervention Description
Provided twice a day between meals.
Primary Outcome Measure Information:
Title
Changes in integrated fractional synthesis rate (%/d) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Integrative myofibrillar fractional synthesis rate will be calculated during baseline (day 0-5) and bed rest (day 5-10) phases.
Time Frame
Day 0-5 and day 5-10
Secondary Outcome Measure Information:
Title
Changes in whole body insulin sensitivity in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Measurements taken in the fasted state before and after bed rest. Will measure blood glucose and insulin concentration during a hyperinsulinemic-euglycemic clamp.
Time Frame
Day-3 and Day 10.
Title
Changes in whole-body lean mass (kg) in response to bed rest with and without ketone monoester (KET) supplementation
Description
Measurements taken in the fasted state using dual-energy x-ray absorptiometry (DXA) following urinary void before and after bed rest.
Time Frame
Day-3 and Day 10.
Title
Changes in leg lean mass (kg) in response to bed rest with and without ketone monoester (KET) supplementation
Description
Measurements taken in the fasted state using dual-energy x-ray absorptiometry (DXA) following urinary void before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in quadriceps muscle volume in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Measurements taken before and after bed rest via magnetic resonance imaging (MRI).
Time Frame
Day -3 and Day 10.
Title
Changes in maximal voluntary isometric contraction (N/m) of the knee extensors in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Measurements taken before and after bed rest using a Biodex dynamometer.
Time Frame
Day -3 and Day 10.
Title
Changes in handgrip strength (kg) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Measurements taken before and after bed rest using a Jamar hand dynamometer.
Time Frame
Day -3 and Day 10.
Title
Changes in physical performance (numerical score) as determined by short physical performance battery (SPPB) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Measurements taken before and after bed rest
Time Frame
Day -3 and Day 10.
Title
Changes in physical performance (numerical score) as determined by 5-item physical performance test in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Measurements taken before and after bed rest
Time Frame
Day -3 and Day 10.
Title
Changes in cognitive status in response to bed rest with and without ketone monoester (KET) supplementation.
Description
NIH Toolbox Cognition Battery (computerized). Measurements taken before and after bed rest
Time Frame
Day 4 and Day 9.
Title
Changes in markers of inflammation in systemic circulation in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Markers of inflammation including: IL-1 beta, NF-K beta 1, IL-6, TNF-alpha, IFNY, MIP-1 beta will be evaluated. Measurements taken before, during, and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in muscle mRNA expression of inflammatory regulators will be assessed in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Muscle mRNA expression of NFKB1, TLR-4,IL-6, TNF-alpha, and IL-1Beta will be evaluated. Measurements taken before and after bed rest
Time Frame
Day -3 and Day 10.
Title
Changes in skeletal muscle phenotype in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Muscle cross-sections immunolabeled for type I, IIa, and IIx myosin heavy chains. Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in skeletal muscle fiber size in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Muscle cross-sections analyzed for cross-sectional area.
Time Frame
Day -3 and Day 10.
Title
Changes in mitochondrial content in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Via the assessment in succinate dehydrogenase activity.
Time Frame
Day -3 and Day 10.
Title
Changes in mitochondrial respiration in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Assessed using standard substrate and inhibitor addition protocols in O2k high resolution Respirometer. Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in mitochondrial calcium retention capacity (marker of mitochondrial propensity to trigger apoptosis) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Determined spectrofluorometrically using the Calcium Green probe. Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in mitochondrial reactive oxygen species (ROS) production in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Assessed using standard substrate and inhibitor addition protocols in O2k high resolution Respirometer. Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in mitochondrial time to the permeability transition pore opening (marker of mitochondrial propensity to trigger apoptosis) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Determined spectrofluorometrically using the Calcium Green probe. Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in the phosphorylation status of anabolic signaling molecules modulating muscle protein synthesis (MPS) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Western blotting - membranes will be probed with phospho-specific antibodies against IRS-1S527/Thr446, AktSer473, mTORSer2448, 4E-BP1Thr37/46, rpS6Ser240/244, p70S6KThr389. Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in the phosphorylation status of catabolic signaling molecules modulating muscle protein breakdown (MPB) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Western blotting - membranes will be probed with phospho-specific antibodies against FoxO3aThr32, MuRF1, and MAFbx. Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Blood beta-hydroxybutyrate concentrations (mmol/L) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Measurements taken at the start and end of bed rest.
Time Frame
Day 5 and Day 10
Title
Changes in subjective pain via visual analog scale in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Throughout the 5 day bed rest period.
Time Frame
Day 5-10.
Title
Changes in muscle area in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Peripheral quantitative computed tomography (pQCT). Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Changes in muscle density in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Peripheral quantitative computed tomography (pQCT). Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
2H enrichments in body water before and during bed rest with and without ketone monoester (KET) supplementation.
Description
Throughout the baseline and bed rest period.
Time Frame
Day -1 to Day 10.
Title
2H-alanine enrichment in venous blood before and during bed rest with and without ketone monoester (KET) supplementation.
Description
Throughout the baseline and bed rest period.
Time Frame
Day -1 to Day 10.
Title
Changes in resting metabolic rate (RMR) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Measurements taken before and after bed rest.
Time Frame
Day -3 and Day 10.
Title
Physical activity level via accelerometer before bed rest.
Description
Throughout the baseline period
Time Frame
Day 0-4.
Title
Changes in sleep disturbance (numerical score) during bed rest with and without ketone monoester (KET) supplementation.
Description
Via Patient-Reported Outcomes Measurement Information System (PROMIS) Short form 8a. Measured throughout the 5 day bed rest period.
Time Frame
Day 5-10.
Title
Changes in sleep quality (numerical score) during bed rest with and without ketone monoester (KET) supplementation.
Description
Via Pittsburgh Sleep Quality Index (PSQI). Measured throughout the 5 day bed rest period.
Time Frame
Day 5-10.
Title
Average habitual dietary intake assessed using Keenoa for 3 days (a food tracker application).
Description
Dietary intake will be assessed for total energy (kcals) and macronutrient (protein, carbohydrate, and fat consumption; g) intake.
Time Frame
Measured before bed rest.
Title
Changes in Thigh Absolute Synthetic Rate (ASR) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Changes in Thigh Absolute Synthetic Rate (ASR) will be calculated during baseline (day 0-5) and bed rest (day 5-10) phases.
Time Frame
Day 0-5 and day 5-10
Title
Changes in Thigh Absolute Protein Breakdown Rate (ABR) in response to bed rest with and without ketone monoester (KET) supplementation.
Description
Changes in Thigh Absolute Protein Breakdown Rate (ABR) will be calculated during baseline (day 0-5) and bed rest (day 5-10) phases.
Time Frame
Day 0-5 and day 5-10

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy, male, and female, older adults. Healthy will be defined as screen by the 2020 PAR-Q+, medical screening questionnaire, GAQ, and COVID-19 symptom questionnaire patient screening. 'Older' will be defined as being 65-85 years of age. Participants are required to not engage in structured resistance training for at least 6 months prior to participation in the study. Participants are willing to abide by the compliance rules of this study. Exclusion Criteria: Pre-menopausal females: Women must be postmenopausal having not menstruated for at least 1 year prior to study participation. Hormonal fluctuations associated with the menstrual cycle have been reported to alter protein metabolism and may influence indices of muscle protein synthesis and breakdown (69-71). BMI <18.5 or > 30 kg ∙ m-2. Self-reported regular tobacco use and vaping products. Self-reported illicit drug use (e.g., growth hormone, testosterone, etc.) Individuals who have participated in studies within the past year involving a stable isotope of 2H. A history of thrombosis, diagnosed with type 2 diabetes mellitus by physician or HbA1c values of > 7.0%, dementia, coronary artery disease, musculoskeletal/orthopedic disorders, and severe allergies. The use of medications known to modulate skeletal muscle metabolism (e.g., corticosteroids, hormone replacement therapy, non-steroidal anti-inflammatory drugs, metformin). The use of over-the-counter supplements (protein supplements, creatine, fish oil). Inability to adhere to any of the compliance rules judged by the principal investigator or medical doctor.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tyler A Churchward-Venne, PhD
Phone
5143984184
Ext
00839
Email
tyler.churchward-venne@mcgill.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Sarkis J Hannaian, MSc
Phone
5149748066
Email
sarkis.hannaian@mail.mcgill.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tyler A Churchward-Venne, PhD
Organizational Affiliation
McGill University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Institute - McGill University Health Centre
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sharmila Balram
Email
sharmila.balram@affiliate.mcgill.ca
First Name & Middle Initial & Last Name & Degree
Tyler Churchward-Venne, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Exogenous Ketosis During Bed Rest in Older Adults

We'll reach out to this number within 24 hrs